Xenon Pharmaceuticals (XENE)

• Market cap: $2.94B
• 1 day: -2.78%
• 5 days: 0.63%
• 1 month: -6.69%
• 3 months: -11.06%
• 6 months: -8.48%
• Year to date: -4.11%
• 1 year: -15.58%
• 5 years: 121.38%
• 10 years: 114.36%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada.

Employees: 259

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

321% more call options, than puts

Call options by funds: $4.78M | Put options by funds: $1.13M

21% more repeat investments, than reductions

Existing positions increased: 74 | Existing positions reduced: 61

13% more funds holding in top 10

Funds holding in top 10: 8 [Q2] → 9 (+1) [Q3]

2% more capital invested

Capital invested by funds: $2.93B [Q2] → $2.99B (+$61.9M) [Q3]

0.68% more ownership

Funds ownership: 99.43% [Q2] → 100.11% (+0.68%) [Q3]

5% less funds holding

Funds holding: 211 [Q2] → 200 (-11) [Q3]

39% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 23

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $53 38% upside
• Avg. target: $57 47% upside
• High target: $60 56% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Douglas Tsao 33% 1-year accuracy 56 / 172 met price target	38% upside $53	Buy Reiterated	12 Dec 2024
Needham Serge Belanger 36% 1-year accuracy 47 / 129 met price target	56% upside $60	Buy Reiterated	13 Nov 2024